The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice

Laboratory Investigation

Volumn 90, Issue 6, 2010, Pages 844-852

  Fickert, Peter ^a   Thueringer, Andrea ^a   Moustafa, Tarek ^a   Silbert, Dagmar ^a   Gumhold, Judith ^a   Tsybrovskyy, Oleksiy ^a   Lebofsky, Margitta ^b   Jaeschke, Hartmut ^b   Denk, Helmut ^a   Trauner, Michael ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Bile acids; Cholangiocytes; Cholestasis; Cytokines; Ductular reaction; Sclerosing cholangitis

Indexed keywords

CCL2 PROTEIN, MOUSE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL; ARTICLE; C57BL MOUSE; CHOLANGITIS; DISEASE MODEL; GALLBLADDER DISEASE; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; LIVER; MALE; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CHEMOKINE CCL2; CHOLANGITIS; DISEASE MODELS, ANIMAL; GALLBLADDER DISEASES; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPONTIN; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954568757     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.61     Document Type: Article

References (51)

1. Lazaridis KN, Strazzabosco M, LaRusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577.
2. Lu BR, Mack CL. Inflammation and biliary tract injury. Curr Opin Gastroenterol 2009;25:260-264.
3. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005;39(4 Suppl 2):S90-S102.
4. Xia X, Demorrow S, Francis H, et al. Cholangiocyte injury and ductopenic syndromes. Semin Liver Dis 2007;27:401-412.
5. Zatloukal K, Stumptner C, Fuchsbichler A, et al. The keratin cytoskeleton in liver diseases. J Pathol 2004;204:367-376.
6. Fickert P, Stoger U, Fuchsbichler A, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 2007;171:525-536.
7. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
8. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009;130:16-26.
9. Parola M, Marra F, Pinzani M. Myofibroblast—like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Aspects Med 2008;29:58-66.
10. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004;84:153-159.
11. Whitington PF, Malladi P, Melin-Aldana H, et al. Expression of osteopontin correlates with portal biliary proliferation and fibrosis in biliary atresia. Pediatr Res 2005;57:837-844.
12. Apte UM, Banerjee A, McRee R, et al. Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis. Toxicol Appl Pharmacol 2005;207:25-38.
13. Zeisberg M, Kalluri R. The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 2004;82:175-181.
14. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429-1437.
15. Demetris AJ, Specht S, Nozaki I, et al. Small proline-rich proteins (SPRR) function as SH3 domain ligands, increase resistance to injury and are associated with epithelial-mesenchymal transition (EMT) in cholangiocytes. J Hepatol 2008;48:276-288.
16. Omenetti A, Porrello A, Jung Y, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 2008;118:3331-3342.
17. Robertson H, Kirby JA, Yip WW, et al. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 2007;45:977-981.
18. Rygiel KA, Robertson H, Marshall HL, et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008;88:112-123.
19. Syn WK, Jung Y, Omenetti A, et al. Hedgehog-mediated epithelial-tomesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009;137:1478-1488.
20. Yue HY, Yin C, Hou JL, et al. Hepatocyte nuclear factor 4α attenuates hepatic fibrosis in rats. Gut 2010;59:236-246.
21. Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007;282:23337-23347.
22. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;9:299-314.
23. Rutherford A, Chung RT. Acute liver failure: mechanisms of hepatocyte injury and regeneration. Semin Liver Dis 2008;28:167-174.
24. Sheikh MY, Choi J, Qadri I, et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008;47:2127-2133.
25. Bahcecioglu IH, Koca SS, Poyrazoglu OK, et al. Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachlorideinduced hepatic fibrosis. Inflammation 2008;31:215-221.
26. Koca SS, Bahcecioglu IH, Poyrazoglu OK, et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet. Inflammation 2008;31:91-98.
27. Trauner M, Arrese M, Soroka CJ, et al. The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis. Gastroenterology 1997;113:255-264.
28. Aron JH, Bowlus CL. The immunobiology of primary sclerosing cholangitis. Semin Immunopathol 2009;31:383-397.
29. O’Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006;26:3-21.
30. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005;4:137-143.
31. Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med 2008;29:50-57.
32. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115: 209-218.
33. Lorena D, Darby IA, Gadeau AP, et al. Osteopontin expression in normal and fibrotic liver. Altered liver healing in osteopontin-deficient mice. J Hepatol 2006;44:383-390.
34. Zhao L, Li T, Wang Y, et al. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008;62:1056-1062.
35. Sahai A, Malladi P, Melin-Aldana H, et al. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am J Physiol Gastrointest Liver Physiol 2004;287:G264-G273.
36. Sahai A, Malladi P, Pan X, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004;287:G1035-G1043.
37. Harada K, Ozaki S, Sudo Y, et al. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathol Int 2003;53:8-17.
38. Nakken KE, Nygard S, Haaland TK, et al. Gene expression profiles reflect sclerosing cholangitis activity in abcb4 (_/_) mice. Scand J Gastroenterol 2009;44:211-218.
39. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123: 1238-1251.
40. Slott PA, Liu MH, Tavoloni N. Origin, pattern, and mechanism of bile duct proliferation following biliary obstruction in the rat. Gastroenterology 1990;99:466-477.
41. Wagner M, Fickert P, Zollner G, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003;125:825-838.
42. Wiener SM, Hoyt Jr RF, Deleonardis JR, et al. Manometric changes during retrograde biliary infusion in mice. Am J Physiol Gastrointest Liver Physiol 2000;279:G49-G66.
43. You J, Reilly GC, Zhen X, et al. Osteopontin gene regulation by oscillatory fluid flow via intracellular calcium mobilization and activation of mitogen-activated protein kinase in MC3T3-E1 osteoblasts. J Biol Chem 2001;276:13365-13371.
44. Wongkhantee S, Yongchaitrakul T, Pavasant P. Mechanical stress induces osteopontin via ATP/P2Y1 in periodontal cells. J Dent Res 2008;87:564-568.
45. Iizuka K, Murakami T, Kawaguchi H. Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells. Biochem Biophys Res Commun 2001;283:493-498.
46. Endlich N, Sunohara M, Nietfeld W, et al. Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress. FASEB J 2002;16: 1850-1852.
47. Adams DH, Afford SC. The role of cholangiocytes in the development of chronic inflammatory liver disease. Front Biosci 2002;7:e276-e285.
48. Essani NA, Bajt ML, Farhood A, et al. Transcriptional activation of vascular cell adhesion molecule-1 gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Immunol 1997;158:5941-5948.
49. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007;13:1424-1429.
50. Silveira MG, Lindor KD. Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol 2008;14: 3338-3349.
51. Ponnuraj EM, Hayward AR. Requirement for TNF-Tnfrsf1 signalling for sclerosing cholangitis in mice chronically infected by Cryptosporidium parvum. Clin Exp Immunol 2002;128:416-420.